Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PETS's Cash to Debt is ranked higher than
96% of the 566 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.48 vs. PETS: No Debt )
PETS' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.92
PETS's Equity to Asset is ranked higher than
99% of the 565 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.41 vs. PETS: 0.92 )
PETS' s 10-Year Equity to Asset Range
Min: -0.13   Max: 0.95
Current: 0.92

-0.13
0.95
Interest Coverage No Debt
PETS's Interest Coverage is ranked higher than
94% of the 426 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 12.14 vs. PETS: No Debt )
PETS' s 10-Year Interest Coverage Range
Min: 15.27   Max: 9999.99
Current: No Debt

15.27
9999.99
F-Score: 6
Z-Score: 36.02
M-Score: -3.41
WACC vs ROIC
14.21%
63.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 11.81
PETS's Operating margin (%) is ranked higher than
97% of the 568 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.36 vs. PETS: 11.81 )
PETS' s 10-Year Operating margin (%) Range
Min: -26.37   Max: 17.02
Current: 11.81

-26.37
17.02
Net-margin (%) 7.47
PETS's Net-margin (%) is ranked higher than
96% of the 568 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.16 vs. PETS: 7.47 )
PETS' s 10-Year Net-margin (%) Range
Min: -28.25   Max: 10.91
Current: 7.47

-28.25
10.91
ROE (%) 23.88
PETS's ROE (%) is ranked higher than
94% of the 558 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.90 vs. PETS: 23.88 )
PETS' s 10-Year ROE (%) Range
Min: -236.77   Max: 90.8
Current: 23.88

-236.77
90.8
ROA (%) 21.35
PETS's ROA (%) is ranked higher than
100% of the 570 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.08 vs. PETS: 21.35 )
PETS' s 10-Year ROA (%) Range
Min: -52.2   Max: 47.63
Current: 21.35

-52.2
47.63
ROC (Joel Greenblatt) (%) 109.21
PETS's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 569 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.27 vs. PETS: 109.21 )
PETS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -165.66   Max: 194.27
Current: 109.21

-165.66
194.27
Revenue Growth (3Y)(%) 4.40
PETS's Revenue Growth (3Y)(%) is ranked higher than
74% of the 481 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.60 vs. PETS: 4.40 )
PETS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 2.7   Max: 57.8
Current: 4.4

2.7
57.8
EBITDA Growth (3Y)(%) -1.60
PETS's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 449 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.10 vs. PETS: -1.60 )
PETS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -8.7   Max: 109.3
Current: -1.6

-8.7
109.3
EPS Growth (3Y)(%) -0.70
PETS's EPS Growth (3Y)(%) is ranked higher than
71% of the 420 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.30 vs. PETS: -0.70 )
PETS' s 10-Year EPS Growth (3Y)(%) Range
Min: -9   Max: 104.1
Current: -0.7

-9
104.1
» PETS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PETS Guru Trades in Q1 2014

John Burbank 13,364 sh (New)
Paul Tudor Jones 33,500 sh (New)
Chuck Royce 351,500 sh (+149.29%)
John Hussman 26,000 sh (+30%)
John Buckingham 130,106 sh (+6.74%)
Jim Simons 1,817,208 sh (-4%)
» More
Q2 2014

PETS Guru Trades in Q2 2014

John Buckingham 132,974 sh (+2.2%)
Chuck Royce 351,500 sh (unchged)
Paul Tudor Jones Sold Out
John Hussman Sold Out
John Burbank Sold Out
Jim Simons 1,695,407 sh (-6.7%)
» More
Q3 2014

PETS Guru Trades in Q3 2014

John Buckingham 136,162 sh (+2.4%)
Chuck Royce 351,500 sh (unchged)
Jim Simons 1,589,215 sh (-6.26%)
» More
Q4 2014

PETS Guru Trades in Q4 2014

John Buckingham 137,816 sh (+1.21%)
Jim Simons 1,600,615 sh (+0.72%)
Chuck Royce 351,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PETS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Sold Out 0.03%$12.63 - $13.8 $ 15.3917%0
John Burbank 2014-06-30 Sold Out $12.63 - $13.8 $ 15.3917%0
John Hussman 2014-03-31 Add 30%0.01%$12.62 - $16.65 $ 15.3910%26000
John Burbank 2014-03-31 New Buy$12.62 - $16.65 $ 15.3910%13364
John Hussman 2013-12-31 Add 33.33%0.01%$14.58 - $16.86 $ 15.39-1%20000
Joel Greenblatt 2013-09-30 Sold Out 0.02%$12.82 - $17.17 $ 15.39-2%0
Joel Greenblatt 2013-06-30 Reduce -78.51%0.08%$12.37 - $13.73 $ 15.3918%32909
John Hussman 2013-06-30 New Buy0.01%$12.37 - $13.73 $ 15.3918%15000
Joel Greenblatt 2013-03-31 Add 39.37%0.03%$11.09 - $14.37 $ 15.3920%153161
Joel Greenblatt 2012-06-30 Add 162.75%0.06%$11.15 - $13.46 $ 15.3926%102679
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.00
PETS's P/E(ttm) is ranked higher than
85% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 25.50 vs. PETS: 18.00 )
PETS' s 10-Year P/E(ttm) Range
Min: 11.25   Max: 50.06
Current: 18

11.25
50.06
Forward P/E 17.48
PETS's Forward P/E is ranked higher than
82% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.76 vs. PETS: 17.48 )
N/A
PE(NRI) 17.90
PETS's PE(NRI) is ranked higher than
86% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 25.70 vs. PETS: 17.90 )
PETS' s 10-Year PE(NRI) Range
Min: 11.19   Max: 50.9
Current: 17.9

11.19
50.9
P/B 4.24
PETS's P/B is ranked higher than
60% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.53 vs. PETS: 4.24 )
PETS' s 10-Year P/B Range
Min: 2.33   Max: 19.39
Current: 4.24

2.33
19.39
P/S 1.36
PETS's P/S is ranked higher than
59% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.56 vs. PETS: 1.36 )
PETS' s 10-Year P/S Range
Min: 0.84   Max: 3.51
Current: 1.36

0.84
3.51
PFCF 12.41
PETS's PFCF is ranked higher than
90% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 40.73 vs. PETS: 12.41 )
PETS' s 10-Year PFCF Range
Min: 7.86   Max: 1221.5
Current: 12.41

7.86
1221.5
POCF 12.31
PETS's POCF is ranked higher than
76% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.33 vs. PETS: 12.31 )
PETS' s 10-Year POCF Range
Min: 7.64   Max: 305.38
Current: 12.31

7.64
305.38
EV-to-EBIT 9.79
PETS's EV-to-EBIT is ranked higher than
92% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.67 vs. PETS: 9.79 )
PETS' s 10-Year EV-to-EBIT Range
Min: 4.7   Max: 32.5
Current: 9.79

4.7
32.5
Shiller P/E 16.13
PETS's Shiller P/E is ranked higher than
93% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 35.24 vs. PETS: 16.13 )
PETS' s 10-Year Shiller P/E Range
Min: 9.84   Max: 124.94
Current: 16.13

9.84
124.94
Current Ratio 12.35
PETS's Current Ratio is ranked higher than
99% of the 568 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.15 vs. PETS: 12.35 )
PETS' s 10-Year Current Ratio Range
Min: 0.29   Max: 17.46
Current: 12.35

0.29
17.46
Quick Ratio 8.92
PETS's Quick Ratio is ranked higher than
99% of the 568 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.64 vs. PETS: 8.92 )
PETS' s 10-Year Quick Ratio Range
Min: 0.11   Max: 14.61
Current: 8.92

0.11
14.61
Days Inventory 65.31
PETS's Days Inventory is ranked higher than
62% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 37.42 vs. PETS: 65.31 )
PETS' s 10-Year Days Inventory Range
Min: 28.38   Max: 78.88
Current: 65.31

28.38
78.88
Days Sales Outstanding 2.16
PETS's Days Sales Outstanding is ranked higher than
93% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.82 vs. PETS: 2.16 )
PETS' s 10-Year Days Sales Outstanding Range
Min: 2.31   Max: 6.05
Current: 2.16

2.31
6.05

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.42
PETS's Dividend Yield is ranked higher than
88% of the 480 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.89 vs. PETS: 4.42 )
PETS' s 10-Year Dividend Yield Range
Min: 0.51   Max: 5.85
Current: 4.42

0.51
5.85
Dividend Payout 0.80
PETS's Dividend Payout is ranked higher than
62% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.61 vs. PETS: 0.80 )
PETS' s 10-Year Dividend Payout Range
Min: 0.31   Max: 1.21
Current: 0.8

0.31
1.21
Dividend growth (3y) 11.60
PETS's Dividend growth (3y) is ranked higher than
87% of the 380 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.20 vs. PETS: 11.60 )
PETS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 26
Current: 11.6

0
26
Yield on cost (5-Year) 10.90
PETS's Yield on cost (5-Year) is ranked higher than
97% of the 485 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.14 vs. PETS: 10.90 )
PETS' s 10-Year Yield on cost (5-Year) Range
Min: 1.26   Max: 14.5
Current: 10.9

1.26
14.5
Share Buyback Rate 4.00
PETS's Share Buyback Rate is ranked higher than
95% of the 384 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.20 vs. PETS: 4.00 )
PETS' s 10-Year Share Buyback Rate Range
Min: 4.1   Max: -48.2
Current: 4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.73
PETS's Price/Net Cash is ranked higher than
99% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.00 vs. PETS: 6.73 )
PETS' s 10-Year Price/Net Cash Range
Min: 3.77   Max: 34.59
Current: 6.73

3.77
34.59
Price/Net Current Asset Value 5.37
PETS's Price/Net Current Asset Value is ranked higher than
99% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.00 vs. PETS: 5.37 )
PETS' s 10-Year Price/Net Current Asset Value Range
Min: 3.12   Max: 236
Current: 5.37

3.12
236
Price/Tangible Book 4.29
PETS's Price/Tangible Book is ranked higher than
73% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.68 vs. PETS: 4.29 )
PETS' s 10-Year Price/Tangible Book Range
Min: 1.56   Max: 36.5
Current: 4.29

1.56
36.5
Price/DCF (Projected) 1.18
PETS's Price/DCF (Projected) is ranked higher than
91% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.70 vs. PETS: 1.18 )
PETS' s 10-Year Price/DCF (Projected) Range
Min: 0.54   Max: 13.76
Current: 1.18

0.54
13.76
Price/Median PS Value 0.87
PETS's Price/Median PS Value is ranked higher than
92% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.26 vs. PETS: 0.87 )
PETS' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 2
Current: 0.87

0.14
2
Price/Graham Number 1.86
PETS's Price/Graham Number is ranked higher than
82% of the 596 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.13 vs. PETS: 1.86 )
PETS' s 10-Year Price/Graham Number Range
Min: 1.06   Max: 5.73
Current: 1.86

1.06
5.73
Earnings Yield (Greenblatt) 10.20
PETS's Earnings Yield (Greenblatt) is ranked higher than
92% of the 566 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.90 vs. PETS: 10.20 )
PETS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 21.2
Current: 10.2

3.1
21.2
Forward Rate of Return (Yacktman) 2.64
PETS's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 451 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.57 vs. PETS: 2.64 )
PETS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.7   Max: 65.7
Current: 2.64

0.7
65.7

Analyst Estimate

Mar15 Mar16
Revenue(Mil) 228 223
EPS($) 0.92 0.88
EPS without NRI($) 0.92 0.88

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, GNC, APNHY, JCOUF, PMC » details
Traded in other countries:PQM.Germany,
PetMed Express, Inc. was incorporated in the state of Florida in January 1996. The company is a nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. The Company offers consumers an alternative for obtaining pet medications in terms of convenience, price, and speed of delivery. Its current product line contains approximately 3000 SKUS. These products include a majority of the well-known brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx, and Rimadyl. These pet supplies include: food, beds, crates, stairs, strollers, and other popular pet supplies. Its website allows customers to easily browse and purchase all of its products online. Its operations are subject to regulation by the State of Florida and are licensed as a community pharmacy by the Florida Board of Pharmacy.
» More Articles for PETS

Headlines

Articles On GuruFocus.com
mfi march 2015 Feb 25 2015 
Bob Olstein Says Forget Amazon, Buy PetSmart, Teradata Jun 13 2014 
PetMed Express Inc. Is Trying Harder to Push Sales Apr 21 2014 
4 Cash Gushing, Undervalued Small Cap Stocks With Zero Debt Apr 08 2014 
4 Biggest Dividend Challengers with Low Debt and Nice Initial Yields Aug 28 2013 
12 Dividend Stocks Sending More Cash to Shareholders Aug 05 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
comment on PETS Mar 02 2013 
comment on PETS Mar 02 2013 
PetMed Express - Debt-Free with Attractive Dividend Yield Nov 26 2012 


More From Other Websites
Amazon Hits New 52-Week High due to Strong Q4 Earnings - Analyst Blog Feb 27 2015
Priceline (PCLN) Prices EUR 1B Unsecured Senior Notes - Analyst Blog Feb 26 2015
Inaugural Books from Amazon Kindle Scout Next Week - Analyst Blog Feb 25 2015
Is Amazon Considering Distribution Center in Shakopee? - Analyst Blog Feb 25 2015
Should You Get Rid of zulily (ZU) Now? - Tale of the Tape Feb 25 2015
FotoNation Buys Smart Sensors for Biometric Capabilities - Analyst Blog Feb 24 2015
Amazon (AMZN) Approves Original Kids Series, Season 2 - Analyst Blog Feb 24 2015
Why Blue Nile (NILE) Could Be Positioned for a Slump - Tale of the Tape Feb 24 2015
Carl Icahn Increases Stake in eBay, Should You Buy It Too? - Analyst Blog Feb 23 2015
Google, Mattel Collaborate to Bring Advanced View-Master - Analyst Blog Feb 23 2015
Yet-to-be Launched Jet.com Raises $140M. Should Amazon Take Note? - Analyst Blog Feb 20 2015
Google's YouTube Set to Roll Out Kids App Next Week - Analyst Blog Feb 20 2015
Pinterest Looking at $11B Valuation with Latest Funding? - Analyst Blog Feb 19 2015
Amazon OKs Comedy Show 'Mozart in the Jungle' Season 2 - Analyst Blog Feb 19 2015
Amazon Prime Now: 1-Hour Delivery in NYC - Analyst Blog Feb 18 2015
Will FAA Make Amazon Prime Air Just a Dream? - Analyst Blog Feb 17 2015
Vipshop (VIPS) Misses on Q4 Earnings, Beats on Revenues - Analyst Blog Feb 17 2015
Taxi Apps Backed by Alibaba &Tencent to Merge? - Analyst Blog Feb 13 2015
Weakness Seen in zulily (ZU): Stock Tumbles 27% - Tale of the Tape Feb 13 2015
Groupon Swings to Earnings in Q4, Shares Fall on Soft View - Analyst Blog Feb 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK